BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12749509)

  • 1. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
    West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
    Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
    Torres A; Bauer TT; León-Gil C; Castillo F; Alvarez-Lerma F; Martínez-Pellús A; Leal-Noval SR; Nadal P; Palomar M; Blanquer J; Ros F
    Thorax; 2000 Dec; 55(12):1033-9. PubMed ID: 11083889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
    Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
    Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
    Shorr AF; Zadeikis N; Jackson WL; Ramage AS; Wu SC; Tennenberg AM; Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S123-9. PubMed ID: 15712100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
    Shorr AF; Susla GB; Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S115-22. PubMed ID: 15712099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
    Geddes A; Thaler M; Schonwald S; Härkönen M; Jacobs F; Nowotny I
    J Antimicrob Chemother; 1999 Dec; 44(6):799-810. PubMed ID: 10590282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
    Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
    Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
    Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A;
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
    Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
    Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM; Soto NE; Melnick DA
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
    Klausner HA; Brown P; Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
    Curr Med Res Opin; 2007 Nov; 23(11):2637-45. PubMed ID: 17880755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
    Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
    Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/cilastatin in the treatment of severe nosocomial pneumonia.
    Potgieter PD; Linton DM; Forder AA; Plumb H
    S Afr Med J; 1988 Oct; 74(8):390-2. PubMed ID: 3187816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
    Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
    J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.